Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

Similar articles for PubMed (Select 22829258)

1.

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ.

Blood Cancer J. 2012 Mar;2(3):e63. doi: 10.1038/bcj.2012.7. Epub 2012 Mar 23. No abstract available.

2.

Paroxysmal nocturnal hemoglobinuria and complement-mediated erythrocyte damage.

Parker CJ.

Curr Opin Hematol. 1994 Mar;1(2):151-6. Review.

PMID:
9371274
3.

Absence of JAK2-V617F in paroxysmal nocturnal haemoglobinuria-associated thrombosis.

Fouassier M, Girodon F, Cleyrat C, Robillard N, Garand R, Hermouet S.

Thromb Haemost. 2009 Jul;102(1):180-2. doi: 10.1160/TH09-03-0140. No abstract available.

PMID:
19572087
4.

No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.

Stijnis C, Kroes WG, Balkassmi S, Marijt EW, van Rossum AP, Bakker E, Vlasveld LT.

Acta Haematol. 2012;128(3):183-6. Epub 2012 Aug 10.

PMID:
22890406
5.
6.

[Syndrome of aplastic anemia-paroxysmal nocturnal hemoglobinuria. Comparative study of the clinical and biological features with the disease paroxysmal nocturnal hemoglobinuria].

Montserrat E, Cervantes F, Marin P, Matutes E, Vives-Corrons JL, GraƱena A, Rozman C.

Med Clin (Barc). 1980 Nov 25;75(9):369-72. Spanish.

PMID:
7464331
7.

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G.

Mol Biol Rep. 2012 Sep;39(9):8663-7. doi: 10.1007/s11033-012-1721-x. Epub 2012 Jun 22.

PMID:
22722988
8.

JAK2 V617F mutation is uncommon in patients with the 3q21q26 syndrome.

Lin P, Luthra R, Nussenzveig RH, Medeiros LJ.

Hum Pathol. 2010 May;41(5):758-62. doi: 10.1016/j.humpath.2009.11.004. Epub 2010 Feb 12.

PMID:
20153505
9.

An unusual cause of cerebral venous sinus thrombosis. Paroxysmal nocturnal hemoglobinuria.

Bi S, Fan J, Dong J, Liu Q.

Neurosciences (Riyadh). 2011 Jul;16(3):267-9.

PMID:
21677620
10.

Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis.

Colaizzo D, Tiscia GL, Bafunno V, Amitrano L, Vergura P, Lupone MR, Grandone E, Guardascione MA, Margaglione M.

Thromb Res. 2011 Sep;128(3):233-6. doi: 10.1016/j.thromres.2011.03.024. Epub 2011 Apr 16.

PMID:
21497883
11.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

PMID:
21435189
12.
13.

Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia.

Nakatani T, Imamura T, Ishida H, Wakaizumi K, Yamamoto T, Otabe O, Ishigami T, Adachi S, Morimoto A.

Pediatr Blood Cancer. 2008 Dec;51(6):802-5. doi: 10.1002/pbc.21730.

PMID:
18802948
14.

[Clinical study on relationship between JAK2 V617F mutation and chronic myeloproliferative disorders].

Zhang Y, Li L, Nie L, Yu Y, Yang YH, Zhang ZQ, Yang L, Xu SC, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2008 Feb;29(2):105-9. Chinese.

PMID:
18681311
15.

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC.

Haematologica. 2008 Jan;93(1):34-40. doi: 10.3324/haematol.11581.

16.

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.

Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M.

J Thromb Haemost. 2007 Jan;5(1):55-61. Epub 2006 Oct 20.

PMID:
17059429
17.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

Cancer. 2006 Nov 1;107(9):2206-11.

18.

The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.

Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P.

Pathol Biol (Paris). 2007 Mar;55(2):85-7. Epub 2006 Aug 9.

PMID:
16901656
19.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.

Br J Haematol. 2005 Nov;131(3):320-8.

PMID:
16225651
20.

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.

Toyama K, Karasawa M, Yamane A, Irisawa H, Yokohama A, Saitoh T, Handa H, Matsushima T, Sawamura M, Miyawaki S, Murakami H, Nojima Y, Tsukamoto N.

Br J Haematol. 2007 Oct;139(1):64-9.

PMID:
17854308
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk